Effective cancer screening methods are used to detect or identify the presence of a specific cancer before the individual shows any symptoms of cancer. Early detection of cancer through screening can save the life of a person who may have died without screening detection. Diagnosing cancer early can also provide a less expensive and more effective treatment than when the cancer progresses requiring more advanced or drastic treatment. Screening tests for common cancers such as breast, colon, prostate, or cervical cancer may be noninvasive or only mildly invasive. Most screening procedures are non-invasive, which is more convenient, convenient for the patient, and does not require any post-operative care for the patient. Screening tests usually have a recommended age and frequency. As you age, your risk of cancer increases and further screening is recommended. There are some considerations on whether to screen or not, for example; whether the cancer is common or fatal, are there detectable symptoms and how reliable are the test results (Bast, 2000). There are currently two mildly invasive screening tests used to detect prostate cancer. They are the digital rectal exam (DRE) and the prostate specific antigen (PSA) blood test. The DRE is a rapid test capable of checking the health of the prostate. A doctor inserts a gloved, lubricated finger into the rectum to palpate the back of the prostate for size, irregularities, or abnormal areas. DRE is the only way a doctor can physically examine the prostate gland. If a doctor detects an irregularity, the conclusion is not necessarily prostate cancer, but a reason to pursue the diagnosis (Bast, 2000). “Prostate-specific antigen (PSA) is a protein produced by prostate cells. ... . half of the paper ......te pins coated with antibodies that bind to tumor cells. When blood passes through the chip, the tumor cells attach themselves and the spots make them glow to make them easier to detect” (Prostate.net, n.d.). This blood test could eliminate tissue sampling and imaging scans (Prostate.net, n.d.). EN2 is a new test for prostate cancer that measures the EN2 protein in urine. “The study found that testing for the protein could accurately identify 66% of men with prostate cancer and correctly exclude the disease in nearly 90% of men without the disease” (National Health Service, 2011). Prostate cancer cases were confirmed with a biopsy. Studies from the University of Surrey, UK, confirmed that “although the EN2 test works well in large-scale testing, the test would not necessarily replace the PSA test” (National Health Service, 2011) but could be used with the PSA (National Health Service)., 2011)